Champions Oncology Q1 FY27 adjusted EBITDA more than doubled to $671,000; revenue rises 8.8% to $15.2 million
CSBR•Champions Oncology reports higher revenue and improved profitability
- Champions Oncology posted revenue of $15.2 million, up 8.8% year over year, for fiscal Q1 ended July 31, 2026.
- GAAP net loss narrowed to $426,000; GAAP operating loss tightened to $409,000.
- Oncology services margin expanded 8 percentage points to 51%, helped by lower third-party radiolabeling costs.
- Non-GAAP adjusted EBITDA more than doubled to $671,000 as improved study execution lifted conversion of contracted work into revenue.
- Management cited increased commercial activity in data offerings while continuing investment in the commercial organization, data platform, radiopharmaceutical capabilities, and target discovery.
